Gastrodin™
Research & developmentA botanical research platform focused on neurodegeneration and cognitive health. The presentation references IND 62,518.
Explore the research ↗Nature. Science. People.
Global Botanical Pharmaceutical Corporation brings botanical research and product development together to explore new possibilities in health and wellness.

Meet GBPC
GBPC focuses on botanical pharmaceutical and nutraceutical development: turning plant-based research into potential health products.
The company’s overview describes work across brain health, vision and metabolic health, alongside oral film delivery technology. It also highlights a partnership with the American Botanical Drug Association (ABDA).
Our science
A simple introduction to the botanical platforms described in the GBPC presentation.
A botanical research platform focused on neurodegeneration and cognitive health. The presentation references IND 62,518.
Explore the research ↗A liposome and micelle delivery approach described for botanical ingredients including lutein and astaxanthin.
Explore the technology ↗A bitter melon platform presented as part of GBPC’s work in metabolic health and botanical product development.
Explore the platform ↗These descriptions summarize the supplied presentation. An IND reference does not mean a product has FDA approval.
Delivery made simpler
GBPC’s oral dissolving film strip technology is designed as an alternative to swallowing a conventional pill or capsule.
Select the image for a closer look.
Product concepts
Explore three oral film strip concepts featured in the presentation.
A vision-focused oral film strip concept featuring lutein SSL™ technology.
A brain health oral film strip concept featuring micronized gastrodin.
A metabolic health oral film strip concept featuring sustained-release bitter melon.
Product imagery and descriptions come from the presentation. Availability and regulatory status are not confirmed on this website.
IPO & asset value
Asset values and growth plans reported in the GBPC overview presentation.
Across three flagship botanical platforms.
$230 million
Reported value of the neurological health platform, referenced in the presentation alongside IND 62,518.
$210 million
Reported value of the diabetes and metabolic health platform.
$570 million
Reported value of the advanced vision health platform and SSL delivery technology.
Source: presentation, page 2, which attributes these values to Grant Thornton China. The underlying valuation report and valuation date were not supplied. These are reported asset values, not a verified current company valuation, share price or expected investment return. Explore the asset portfolio ↗
The presentation describes Gastrodin’s oral dissolving film strip platform as positioned for IPO-driven expansion.
No IPO filing, exchange, ticker, listing date or offer price is provided in the presentation. This section describes the stated ambition; it does not confirm an active public offering.
Explore the IPO plans ↗The presentation proposes funding research, formulation development, manufacturing, regulatory work and commercialization.
Year 1: $40 million
Commercial launch & market entry
Year 2: $80 million
Oral film strip market expansion
Year 3: $340 million
Accelerated revenue growth
These are projections from page 25, not actual revenue or guaranteed results. The presentation does not assign calendar years to these figures. Explore the revenue projections ↗
Our people
Research, business, finance and operations. Select a name to read a short biography.

Helped establish GBPC’s botanical research foundation. His work connected traditional botanical knowledge with molecular pharmacology and drug development.

Co-founder of the American Botanical Drug Association, with a background in botanical research partnerships, technology entrepreneurship and wellness.

More than 30 years of experience in healthcare management, corporate strategy, international business and product development. Creator of Strip Melts® oral thin film strips.

Experience in financial analysis, strategic planning, sustainable finance and advanced analytics. Holds an MBA from NYU Stern and a BS in Accounting from Rutgers University.

Brings experience in technology, sales and business development, with degrees in electrical engineering and computer science.

More than two decades of experience in contract negotiation, corporate compliance and regulatory compliance. Holds degrees from Vanderbilt, Belmont and Hamilton College.

A 40-year career across public accounting, financial reporting and business operations. Founder and managing partner of Rago, Griesser & Company.

An entrepreneur and finance professional with experience in international business relationships and investment.

Experience in publishing, corporate leadership, partnerships and global nutraceutical and pharmaceutical businesses.

A leadership trainer and organizer with experience in administration, fiscal management, operations and wellness education.
Take a closer look
Explore the presentation for detailed science, company background, leadership biographies and business plans.